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Aim: Patients with diabetes mellitus are at high risk of adverse events after 
percutaneous revascularization, with no differences in outcomes between most 
contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of 
sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical 
benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents 
(a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes. 
Methods and results: We did an investigator-initiated, randomized, controlled, 
assessor-blinded trial at 23 sites in Spain. Eligible patients had diabetes and required 
percutaneous coronary intervention. A total of 1175 patients were randomly assigned 
(1:1) to receive Cre8 EVO or Resolute Onyx stents. The primary endpoint was target-
lesion failure, defined as a composite of cardiac death, target-vessel myocardial 
infarction, and clinically indicated target-lesion revascularization at 1-year follow-up. 
The trial had a non-inferiority design with a 4% margin for the primary endpoint. A 
superiority analysis was planned if non-inferiority was confirmed. There were 106 
primary events, 42 (7.2%) in the Cre8 EVO group and 64 (10.9%) in the Resolute 
Onyx group [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.44 to 0.96; pnon-
inferiority <0.001; psuperiority = 0.030]. Among the secondary endpoints, Cre8 EVO stents 
had significantly lower rate than Resolute Onyx stents of target-vessel failure (7.5% 
vs 11.1%, HR 0.67, 95% CI 0.46 to 0.99; p = 0.042). Probable or definite stent 
thrombosis and all-cause death were not significantly different between groups. 
Conclusions: In patients with diabetes, Cre8 EVO stents were non-inferior to 
Resolute Onyx stents with regard to target-lesion failure composite outcome. An 
exploratory analysis for superiority at 1 year suggests that the Cre8 EVO stents might 
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Clinical trial registration: ClinicalTrials.gov: NCT03321032. 
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Diabetes mellitus is a major health issue that affects more than 463 million 
human beings worldwide.
1
 These patients often have symptomatic coronary artery 
disease and, as a consequence, percutaneous revascularization of patients with 
diabetes using drug-eluting stents is commonly performed worldwide. Only in the 
United States, 240 000 patients with diabetes undergo percutaneous revascularization 
yearly.
2
 However, results of percutaneous coronary intervention with contemporary 
drug-eluting stents are far from good.
3
 Although the second-generation outperformed 
the first-generation drug-eluting stents,
4
 there has been no further outcome 
improvements in stent technology for patients with diabetes for the past 10 years, and 
the little evidence available suggests no substantial differences in outcomes between 
most contemporary drug-eluting stents in diabetes
5
. 
Cre8 EVO stents are thin-strut stents devoid of polymer that release a medium 
dose of sirolimus formulated with an amphiphilic carrier from laser-dug reservoirs 
located at the stent’s abluminal surface.
6
 The combination of the drug with a carrier 
aims to improve drug delivery to the tissue in patients with diabetes that have dose-
dependent drug resistance,
7,8
 and the thin-device thickness (30% thinner that 
everolimus- or zotarolimus-eluting stents) allows low thrombogenicity and fast 
reendothelialization.
9
 This technology has shown clinical benefits in patients with 
diabetes in several small randomized or non-randomized studies.
10-15
 Thus, in the 
SUGAR trial we sought to compare the Cre8 EVO stent to the Resolute Onyx stent (a 
contemporary polymer-based drug-eluting stent) in patients with diabetes mellitus and 
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The SUGAR trial was an investigator-initiated, prospective, randomized (1:1), 
controlled, parallel group, assessor blinded study that included patients with diabetes 
undergoing percutaneous coronary intervention in 23 hospitals in Spain (Appendix). 
The study design and statistical plan has been described previously in detail
16
. The 
study complied with the provisions of the Declaration of Helsinki and the CONSORT 




Patients were eligible if they were aged 18 years or older, had diabetes 
according to the American Diabetes Association diagnostic criteria,
17
 and had 
symptomatic coronary artery disease or silent ischemia with at least one coronary 
lesion with stenosis >50% suitable for percutaneous coronary intervention. The study 
had an all-comers design with few exclusion criteria: life expectancy <2 years, 
cardiogenic shock at presentation, pregnancy, inability to consent (including shock or 
mechanical ventilation) or conditions that preclude at least one month of dual 
antiplatelet therapy. No restriction was placed on the clinical presentation (chronic or 
acute coronary syndromes, including myocardial infarction with or without ST-
segment elevation), complexity of lesions, the number of treated vessels or the 
number of stents implanted. In cases of left main trunk lesion or multivessel disease, 
each center was required to present the case in the local Heart Team. All patients 
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Randomization and masking 
Patients who met the enrolment criteria were randomized 1:1 to receive either 
Cre8 EVO or Resolute Onyx stents. There was no stratification by center or clinical 
factors. Randomization was performed after successfully crossing the target lesion 
with a coronary wire, using web-based software with a block size of four. Allocation 
of stents was at patient-level, meaning that patients should receive exclusively the 
allocated stent in all lesions after randomization. The adjudication committee was 
blinded to treatment allocation, but patients and treating clinicians were not. 
 
Procedures 
The Cre8 EVO (CID S.p.A, Saluggia, Italy) is a balloon-expandable stent 
manufactured from cobalt chromium L605 alloy with 70 μm strut thickness for the 
2.0-2.25 mm stents and 80 μm for the larger stents. Struts are covered with an ultra-
thin (0.3 μm) passive carbon coating. The Cre8 EVO does not have polymer and, 
therefore, the total-device thickness is 70-80 μm. The antiproliferative drug 
(sirolimus, 90 μg/cm
2
) is loaded into reservoirs, which are dug on the stent’s 
abluminal surface. The sirolimus is formulated with an amphiphilic carrier that 
enhances drug diffusion to the cell. Seventy per cent of the drug is released within the 
first 30 days and the remainder is completely eluted by 90 days. 
The Resolute Onyx (Medtronic, Minneapolis, MN, USA) is a balloon-
expandable stent formed from a single wire bent into a continuous sinusoid pattern 
and then laser fused back onto itself (rather than classical rings and links design). It is 
manufactured from a composite metal material, consisting of a cobalt-based alloy 
shell conforming to ASTM F562 and a platinum-iridium alloy core conforming to 
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4.5-5.0 mm stents. The entire stent is coated (conformal configuration) with a thin 
(5.6 μm), non-erodible and biocompatible Biolynx polymer (which is a blend of two 
different polymers and polyvinyl pyrrolidone). The polymer is designed to release the 
drug (zotarolimus, 160 μg/cm
2
) by 180 days. The total-device thickness is therefore 
92-102 μm. 
Percutaneous coronary intervention was performed according to the current 
standard of care.
18
 There was no restriction to treat complex lesions such as left main, 
bifurcations, chronic total occlusions or those with severe calcification requiring 
rotational atherectomy or other modification devices, following a pragmatic, all-
comers design. Staged procedures were allowed provided that the allocated treatment 
stent was used in all lesions (patient-level randomization). The revascularization 
extent was free to local protocols and investigator’s decision, although complete 
revascularization was strongly encouraged whenever feasible. After the procedure, all 
patients received dual antiplatelet therapy for a minimum of 1 month, although it was 
recommended 3-6 months for chronic coronary syndromes and 12 months for acute 
coronary syndromes. Novel P2Y12 inhibitors (ticagrelor 90 mg BID or prasugrel 10 
mg OD) were encouraged over clopidogrel (75 mg OD) if clinically indicated. If an 
indication for oral anticoagulation was present, the antithrombotic therapy was free to 
investigator’s decision according to local protocols and current guidelines.
19
 Lifestyle 
changes and use of new glucose-lowering drugs with proven cardiovascular safety 
such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 
receptor agonists,
20
 were encouraged. Optimal medical treatment following current 
European Society of Cardiology guidelines with a particular focus on secondary 
prevention was recommended after revascularization.
20,21
 Routine surveillance 






/eurheartj/advance-article/doi/10.1093/eurheartj/ehab790/6420223 by London School of H
ygiene & Tropical M





Cardiac troponin was measured before intervention and at 6-12 h after the 
study procedure, and subsequent serial measurements in case of suspected ischemia. 
In patients with acute coronary syndromes, cardiac biomarkers were measured prior 
to catheterization. To assess adverse events and clinical status, patients were followed 
up by telephone or hospital visit at 1 and 6 months, and by hospital visit at 1 year. 
However, following the coronavirus disease 2019 (COVID-19) pandemic, the steering 
committee and the ethics committee issued an urgent safety warrant on March 12
th
, 
2020 allowing telephone visits at 1-year follow-up for periods when community 
transmission was uncontrolled and healthcare systems were overwhelmed
22
. 
Patient data were captured into secure electronic case report forms. A contract 
research organization monitored the completeness and accuracy of data (Adknoma 
Health Research, Barcelona, Spain). Clinical event adjudication was performed by an 
independent committee in coordination with a central core-laboratory (Barcicore-lab, 
Barcelona, Spain) (Appendix).  
 
Outcomes 
The primary endpoint was target lesion failure, which included cardiac death, 
target-vessel myocardial infarction, or clinically indicated target-lesion 
revascularization. Secondary endpoints included the individual components of the 
primary endpoint, all-cause death, target-vessel revascularization, any 
revascularization, all myocardial infarctions, target-vessel failure, probable or definite 
stent thrombosis and major adverse cardiac events.  





defined in the original study protocol, although due to the changing criteria of 
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definition and the novel Academic Research Consortium (ARC)-2 criteria
24
 were 
obtained. Comprehensive endpoint definitions are listed in the Appendix.  
 
Statistical analysis 
Statistical analyses were performed as previously outlined in the study design 
publication
16
. All analyses were conducted by independent statisticians of the Clinical 
Trials Coordination Unit at Centro Nacional de Investigaciones Cardiovasculares 
Carlos III (CNIC).   
The present study was powered to assess non-inferiority at 1-year of the Cre8 
EVO stent compared to the Resolute Onyx stent. The study was also powered to look 
for superiority at 2 years. If non-inferiority was met at 1 year, a superiority analysis 
was pre-specified. We expected 8.0% and 11.2% of primary events in the Resolute 
Onyx group at 1- and 2-year follow-up, respectively,
25
 and 5% of events for the Cre8 
EVO group at 1-year and 6.5% at 2-year follow-up.
12
 The non-inferiority margin at 1 
year was set at 4% absolute difference (1.5 relative risk of the 8% expected event rate 
of control group). Based on the expected event rate and an anticipated 2% of patients 
lost to follow-up, we calculated that 1164 patients would provide at least 90% power 
with a 1-sided α=0.025 to test for non-inferiority, and 80% power to test superiority 
with a 2-sided α=0.05. 
Analysis was conducted on an intention-to-treat basis, although additional 
analyses were also conducted according to the treatment actually received. 
Categorical variables are reported as frequencies and percentages, whereas continuous 
variables are presented as means (standard deviation), or median (interquartile range) 
where appropriate. Composite endpoints were evaluated as time-to-first event, 
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performed using a Cox proportional-hazards model, although relative risks are also 
reported at the Appendix. At 1 year, a hazard ratio (HR) and its 2-sided 95% 
confidence interval (CI) was estimated. For all comparisons, differences were 
considered statistically significant when p<0.05. STATA software version 15.1 (Stata 
Corp, College Station, TX, USA) was used to perform the analyses. This trial is 
registered with ClinicalTrials.gov, number NCT03321032. 
 
Funding 
The study was funded by the Spanish Society of Cardiology and the Spanish 
Heart Foundation, which had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report.  
 
RESULTS 
Between December 19, 2017, and January 28, 2020, we randomly allocated 
1175 patients with 1548 diseased vessels to receive either Cre8 EVO stents (586 
patients with 879 lesions) or Resolute Onyx stents (589 patients with 950 lesions) 
(Figure 1). Among the 586 patients randomized to Cre8 EVO, 581 actually received 
the allocated stent, whereas there were 3 crossovers, 1 patient received only a non-
study stent and 1 patient was treated with drug-coated balloon angioplasty alone. Two 
patients in this group received a graft stent in addition to the study stent as a bailout 
treatment of a coronary perforation. Among the 589 patients randomized to Resolute 
Onyx, there was 1 crossover and 1 patient received only a non-study stent. No patient 
withdrew consent, 21 died of non-cardiovascular causes and there were 9 patients lost 
to follow-up. Therefore 574 patients in the Cre8 EVO group and 571 patients in the 
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EVO group and 589 patients from the Resolute Onyx group were included in the 
intention-to-treat population. 
Baseline clinical and procedural characteristics are outlined in Table 1 and 
Table 2. Most patients included in the study had type 2 diabetes (95.5%), 32% were 
treated with insulin and 12% were randomized in the setting of a ST-segment 
elevation myocardial infarction. Multivessel disease was present in 50.9% of patients 
and percutaneous coronary intervention of the left main trunk was performed in 4.5% 
of the patients. Syntax score was in the lower tertile in most cases. Baseline and 
procedural characteristics were broadly similar in the two study groups with minor 
differences: patients in the Cre8 EVO stent group were on average 1.4 years older, 
more frequently had cerebrovascular disease and diabetic nephropathy with 3.1 
mL/min less mean creatinine clearance, had fewer lesions per patient and more 
frequently underwent rotational atherectomy and postdilation. Medications at 
discharge and during the study follow-up are detailed in Table 3, and were broadly 
similar in the two study groups, except for a lower frequency of dual antiplatelet 
therapy in the Cre8 EVO group at 1-year follow-up.  
At 1 year, the primary endpoint occurred in 106 patients, 42 (7.2%) in the 
Cre8 EVO group and 64 (10.9%) in the Resolute Onyx group (difference -3.73% 
[95% CI -7.01 to -0.45], one-sided p <0.001 for noninferiority; HR 0.65, 95% CI 0.44 
to 0.96, two-sided p = 0.030 for superiority; Table 4, Figure 2). Relative risk 
estimates were consistent with HRs (Appendix). 
With regard to the secondary endpoints, patients randomized to Cre8 EVO 
stents had significantly lower rates of target-vessel failure than patients randomized to 
Resolute Onyx stents (7.5% vs 11.1%, HR 0.67 [95% CI 0.46 to 0.99], p = 0.042). 
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indicated target-lesion revascularization (2.4% vs 3.9%, p = 0.058) and major adverse 
cardiac events (11.7% vs 15.7%, p = 0.067) in the Cre8 EVO group compared to 
Resolute Onyx. With respect to the other secondary outcomes, there were no 
significant differences between groups (Table 4). The rate of target-vessel myocardial 
infarction was not significantly different regardless of the definition used (per 
protocol or ARC-2) (Appendix). There were two COVID-19-related deaths, one in 
each group.  
In the subgroup analyses we evaluated treatment effect heterogeneity across 
prespecified subgroups (Figure 3). Treatment effect was consistent across all subsets 
of patients since no significant interactions were observed. 
In the as-treated analyses, 1172 patients were included: 582 patients finally 
received Cre8 EVO stents and 590 patients received Resolute Onyx stents.  Their 
findings were largely similar to those obtained in the intention-to-treat approach: Cre8 
EVO stents significantly reduced the rate of primary endpoint target lesion failure 
compared to Resolute Onyx stents (6.9% vs 10.9%, HR 0.62, 95% CI 0.42 to 0.93, p 
= 0.019) (Appendix).  
 
DISCUSSION 
In this trial, we compared Cre8 EVO stents (a stent that releases a formulation 
of antiproliferative drug with a carrier from reservoirs) vs Resolute Onyx stents (a 
contemporary polymer-based drug-eluting stent) in patients with diabetes undergoing 
percutaneous coronary revascularization. We found that patients who received Cre8 
EVO stents had significantly lower rates of the primary composite endpoint target 
lesion failure at 1-year follow-up (Graphical abstract). The results were consistent 
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Patients with diabetes represent up to 38% of patients undergoing 
percutaneous revascularization,
2
 and they are at the highest risk of events after 
percutaneous revascularization with the new-generation drug-eluting stents. For 
example, patients with insulin-treated diabetes mellitus that received the former 
generation of zotarolimus-eluting stents had twice the risk of cardiac death or 
myocardial infarction at 2 years than patients without diabetes,
25
 and percutaneous 
revascularization of patients with diabetes and multivessel disease is associated with 
an increased mortality at 5 years compared to surgical revascularization.
3
 Thus, 
diabetes should be a priority line of research in the ischemic cardiomyopathy field. 
Our study is the first powered trial to compare second-generation drug-eluting 
stents in patients with diabetes, and the first to show a meaningful reduction of events 
after drug-eluting stent implantation in diabetes since the TUXEDO trial,
4
 which 
showed significant reduction of events with everolimus-eluting stents compared to 
first-generation drug-eluting stents. Thereafter, there has been few dedicated trials, 
and the successive subgroup analyses of randomized trials have shown no significant 
differences in outcomes between most polymer-based drug-eluting stents
26,27
. 
Importantly, SUGAR is the first trial that has included a broad population of patients 
with diabetes (all-comers design), and therefore may be considered more 
representative of the real population with diabetes than previous trials. On the 
contrary, previous studies comparing stents had very restrictive exclusion criteria,
4
 
and they systematically excluded complex lesions, left main lesions, chronic total 
occlusions or renal dysfunction. The inclusion of complex lesions and complex 
patients but also for the use of new antiplatelet drugs, new glucose-lowering drugs, 
functional assessment of intermediate lesions and systematic radial approach is a 
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Our findings were consistent with previous studies. In the RESERVOIR trial, 
we showed in a mechanistic way that Cre8 stents effectively reduced neointimal 
hyperplasia in a selected group of patients with diabetes,
12
 and several non-
randomized studies and subgroup analyses
10,13-15
 have shown a reduction of 40-60% 
of events with Cre8 stents compared to other drug-eluting stents in diabetes. Indeed, 
the risk reduction in our study is comparable to the reduction observed in the 




-generation drug-eluting stents.  
In our study, the treatment effect seemed to be relatively constant over time. 
Despite our study was not designed to look for differences in the individual 
components of the primary endpoint, trends towards lower rates of clinically indicated 
target-lesion revascularization and ARC-2 target vessel myocardial infarction were 
observed. Importantly, the curves of target lesion revascularization began to diverge 
at 8-month follow-up, the time-point when restenosis usually begins to become 
clinically evident. Considering the complexity of diabetic patients, a significant 
number of events may be expected after the first year of follow-up. 
The superiority of the Cre8 EVO stent may be related to two stent 
characteristics. First, patients with diabetes had diffuse coronary artery disease and 
more extensive coronary calcification
28
, which may result in a heterogeneous drug 
diffusion. Moreover, patients with diabetes have dose-dependent resistance to 
antiproliferative mTOR inhibitors
8
. Achieving high therapeutic drug concentrations 
along the entire arterial tissue is therefore of special importance in patients with 
diabetes. For these reasons, the formulation of the drug with an amphiphilic carrier, 
which has shown to enhance drug-diffusion in several tissues, may represent an 
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The second distinctive characteristic is the device thickness. Several studies 
have shown that thinner struts are associated with higher shear stress, resulting in 
lower rates of stent restenosis and thrombosis
9,29
. Moreover, a recent meta-analysis 
has shown that ultra-thin stents significantly reduce adverse events compared to 
thicker stents.
30
 In our study, since the polymer of Resolute Onyx is non-erodible, the 
total thickness of the device creating turbulent flow at least during the study follow-up 
is 92-102 µm, which indeed is 16-33% thicker than the Cre8 EVO stent (70-80 µm).  
 In our study, patients received dual antiplatelet therapy and oral 
anticoagulation similarly in both groups up to 6-month follow-up. However, at 1 year, 
the proportion of patients treated with dual antiplatelet therapy was lower in the Cre8 
EVO group. It is likely that, because patients in the Resolute Onyx group had more 
ischemic events such as recurrent revascularizations, dual antiplatelet therapy had to 
be prolonged more frequently, although other factors cannot be ruled out. According 
to this finding, efficacy would be or remarkable interest especially for patients with 
high bleeding risk.  
  
Study limitations 
In our study, the operators were unavoidably unblinded to the randomization 
since both devices have evident differences to the naked eye, so patients may have 
been treated differently on the basis of the allocated device. However, trial outcomes 
were independently adjudicated by a committee, who were blinded to treatment 
allocation, and the data of complete revascularization, interventional techniques or 
medical treatment suggest no group differences in the appropriateness of the treatment 
received. Finally, despite the all-comers study design, around 50% of patients 
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in the lowest Syntax tertile, likely indicating the compliance of the study operators 
with current revascularization guidelines. Consequently, it is uncertain if the Cre8 




In patients with diabetes undergoing percutaneous revascularization, Cre8 
EVO stents were non-inferior to Resolute Onyx stents with regard to target-lesion 
failure composite outcome. An exploratory analysis for superiority at 1 year suggests 
that the Cre8 EVO stents might be superior to the Resolute Onyx stents with regard to 
the same outcome. 
 
Funding: 
This work was supported by the Spanish Society of Cardiology and the 
Spanish Heart Foundation. 
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Table 1. Baseline characteristics. 





General characteristics   
Age at randomization (years) 68.6 (9.8) 67.2 (10.6) 
Male sex 449 (76.6%) 439 (74.5%) 
Medical history   
Hypertension 493 (84.1%) 488 (82.9%) 
Dyslipidemia 485 (82.8%) 471 (80.0%) 
Current smoker 111 (18.9%) 144 (24.4%) 
Prior myocardial infarction 105 (17.9%) 95 (16.1%) 
Prior CABG 21 (3.6%) 15 (2.5%) 
Prior PCI 136 (23.2%) 122 (20.7%) 
Peripheral artery disease 82 (14.0%) 91 (15.4%) 
Cerebrovascular disease 65 (11.1%) 37 (6.3%) 
LVEF 56.6 (11.3) 56.7 (10.8) 
Indication for index procedure   
     Chronic coronary syndromes 243 (41.5%) 229 (38.9%) 
     NSTE-ACS 277 (47.3%) 280 (47.5%) 
     STEMI 66 (11.3%) 80 (13.6%) 
Diabetes and metabolic 
characteristics 
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Years with known diabetes 10.6 (8.7) 11.4 (9.2) 
Insulin-treated diabetes at 
randomization 
183 (31.2%) 194 (32.9%) 
Body mass index 29.4 (5.0) 29.0 (4.5) 
Waist circumference (cm) 103.1 (13.5) 102.5 (12.4) 
LDL cholesterol (mg/dL) 78.8 (44.7) 80.9 (45.5) 
HDL cholesterol (mg/dL) 37.2 (15.9) 38.2 (15.5) 
HbA1c (%) 7.4 (1.5) 7.5 (1.5) 
Creatinine clearance (mL/min) 70.0 (25.4) 73.1 (24.0) 
Hemoglobin (g/L) 13.5 (0.3) 13.8 (0.3) 
CABG = coronary artery bypass graft; HbA1c = glycated hemoglobin; HDL = high-
density lipoprotein; LDL = low-density lipoprotein; LVEF = left ventricular ejection 
fraction; NSTE-ACS = non-ST-elevation acute coronary syndrome; PCI = 
percutaneous coronary intervention; STEMI = ST-elevation myocardial infarction. 
 
Table 2. Procedural characteristics. 







Radial 536 (91.5%) 542 (92.0%) 
Preload with P2Y12 inhibitor 396 (67.6%) 404 (68.6%) 
IIb/IIIa inhibitor 12 (2.0%) 15 (2.5%) 
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Syntax score at randomization* 13.0 (9.7) 13.0 (8.7) 
Number of diseased vessel    
     1 295 (50.3%) 282 (47.9%) 
     2 189 (32.3%) 200 (34.0%) 
     3 102 (17.4%) 107 (18.2%) 
Intracoronary imaging use per vessel 41 (5.4%) 41 (5.2%) 
Number of treated lesions per patient 1.50 (0.83) 1.61 (0.88) 
Number of stents per patient 1.63 (1.02) 1.75 (1.07) 
Complete revascularization 397 (67.7%) 389 (66.0%) 
Staged procedures 21 (3.6%) 30 (5.1%) 
Target vessel at randomization   
     Left main 28 (3.7%) 25 (3.2%) 
     Left anterior descending artery 320 (41.8%) 319 (40.7%) 
     Left circumflex artery 188 (24.6%) 204 (26.1%) 
     Right coronary artery 229 (29.9%) 235 (30.0%) 
TIMI flow 0-1 126 (16.5%) 141 (18%) 
Chronic total occlusion 16 (2.1%) 19 (2.4%) 
Bifurcation with 2 stents 43 (5.6%) 38 (4.9%) 
Aorto-ostial lesion 13 (1.7%) 12 (1.5%) 
AHA/ACC complexity   
     A 72 (9.4%) 67 (8.6%) 
     B1 250 (32.7%) 224 (28.6%) 
     B2 287 (37.5%) 289 (36.9%) 
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Diameter stenosis (%) 83.3 (17.1) 84.7 (15.1) 
Reference vessel diameter by visual 
estimation 
2.98 (0.51) 2.96 (0.50) 
Minimum stent diameter 2.91 (0.49) 2.87 (0.49) 
Total stented length (mm) 26.5 (13.7) 27.4 (14.9) 
Postdilation 286 (37.4%) 226 (28.9%) 
Rotational atherectomy 22 (2.9%) 11 (1.4%) 
Procedural complications   
     No-reflow 4 (0.5%) 5 (0.6%) 
     Dissection 22 (2.9%) 24 (3.1%) 
     Vessel occlusion 4 (0.5%) 1 (0.1%) 
     Coronary perforation 2 (0.3%) 2 (0.3%) 
* Syntax score is self-reported. 
TIMI = Thrombolysis in myocardial infarction; ACC = American College of 
Cardiology; AHA = American Heart Association. 
 
Table 3. Medications and metabolic characteristics at discharge and at follow-up. 







Medication at discharge    
Acetylsalicylic acid 560 (95.6%) 567 (96.3%) 0.54 
P2Y12 inhibitors 0.98 
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     Prasugrel 47 (8%) 47 (8%)  
     Ticagrelor 241 (41.1%) 249 (42.3%)  
Oral anticoagulation 0.41 
     Vitamin K antagonists 25 (4.3%) 17 (2.9%)  
     Non-vitamin K oral 
anticoagulant 
33 (5.6%) 37 (6.3%)  
Statins 513 (87.5%) 517 (87.8%) 0.90 
Glucose-lowering drugs 
     Insulin 200 (34.1%) 219 (37.2%) 0.28 
     Biguanides 392 (66.9%) 408 (69.3%) 0.38 
     Sulfonylureas 53 (9%) 67 (11.4%) 0.19 
     Meglitinides 25 (4.3%) 30 (5.1%) 0.50 
     Thiazolidinediones 1 (0.2%) 0 0.50 
     Dipeptidyl peptidase-4 
inhibitors 
157 (26.8%) 149 (25.3%) 0.56 
     SGLT2 inhibitors 119 (20.3%) 107 (18.2%) 0.35 
     GLP-1 RA 18 (3.1%) 14 (2.4%) 0.46 
Dual antiplatelet therapy    
At 1 month 552 (94.2%) 554 (94.1%) 0.919 
At 6 months 504 (86%) 504 (85.6%) 0.830 
At 12 months 314 (53.6%) 349 (59.3%) 0.050 
Medications at 1 year    
Oral anticoagulation   0.49 
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     Non-vitamin K oral 
anticoagulant 
37 (6.3%) 36 (6.1%)  
Glucose-lowering drugs    
     SGLT2 inhibitors 130 (22.2%) 121 (20.5%) 0.49 
     GLP-1 RA 7 (1.2%) 12 (2.0%) 0.25 
Metabolic characteristics at 1-
year 
   
LDL cholesterol (mg/dL) 65.8 (29.1) 65.6 (28.1) 0.88 
HDL cholesterol (mg/dL) 42.9 (11.8) 44.0 (12.3) 0.17 
HbA1c (%) 7.2 (1.4) 7.4 (1.4) 0.050 
Weight 79.9 (15.0) 80.4 (13.8) 0.61 
     Δ from baseline -1.1 (5.6) -0.6 (6.0) 0.20 
GLP-1 RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated 
hemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; SGLT2 
= sodium-glucose cotransporter 2. 
 
Table 4. Event rates and hazard ratios (95% confidence interval) of primary and 
secondary endpoints at 1-year follow-up. 






HR (95% CI) p-value 
Primary endpoint target 
lesion failure 





of the primary endpoint 
    






/eurheartj/advance-article/doi/10.1093/eurheartj/ehab790/6420223 by London School of H
ygiene & Tropical M

















Other secondary     
All-cause mortality 




















Definite stent thrombosis 




Probable or definite stent 
thrombosis 




     Acute 3 (0.5%) 2 (0.3%) -  
     Subacute 4 (0.7%) 4 (0.7%) -  
     Late 1 (0.2%) 2 (0.3%) -  
Target-vessel failure 
44 (7.5%) 
65 (11.1%) 0.67 (0.46-
0.99) 
0.042 
Major adverse cardiac 
events 
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MI = myocardial infarction. 
* All target-lesion revascularizations were clinically indicated. 
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Figure 2. Primary endpoint and its components. Time-to-event curves are shown for 
patients in the intention-to-treat population who were randomly assigned to receive 
Cre8 EVO stents or Resolute Onyx stents. HR = hazard ratio; CI = confidence 
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Figure 3. Prespecified subgroup analyses of the primary endpoint. HbA1c = glycated 
hemoglobin; LDL = low-density lipoprotein cholesterol; SGLT2i = sodium-glucose 
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